Literature DB >> 3686043

Implications of dose intensity for cancer clinical trials.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3686043

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  1 in total

1.  Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas.

Authors:  S Toma; T Coialbu; L Biassoni; U Folco; C Gatti; G Canavese; A Giacchero; R Rosso
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.